Sales from Eli Lilly’s (NYSE:LLY) newly authorized weight reduction treatment, Zepbound, might attain $4.1B by 2031 within the U.S., a latest report from knowledge analytics agency GlobalData signifies.
According to the report, that’s about half the extent of rival Novo Nordisk’s (NVO) weight reduction remedy Wegovy might generate by that 12 months.
Both Wegovy and Zepbound additionally indicated for Type 2 diabetes, as Ozempic and Mounjaro generated $8.6B and $482.5M in international gross sales in 2022, respectively.
GlobalData’s newest forecast comes shut on the heels of FDA approval of LLY’s GLP-1 receptor agonist, often known as tirzepatide, for power weight administration in adults.
The Indiana-based pharma big plans to launch the product earlier than year-end at a month-to-month listing worth of about $1,060, with a 20% low cost to Wegovy, often known as semaglutide. In October, GlobalData projected Wegovy gross sales within the U.S. might attain $8.1B by 2031.
“Zepbound is Eli Lilly’s first drug which is indicated for obesity, and its arrival to the obesity space is set to raise the competition for Novo Nordisk’s Wegovy (semaglutide) as a gold-standard therapy,” Sara Reci, Senior Pharma Analyst at GlobalData, famous.
Despite hurdles to their uptake, akin to lack of insurance coverage protection and manufacturing constraints, pharma’s give attention to discovering extra efficacious weight reduction medication will propel this indication to a $27.6B worth within the U.S. by 2031, GlobalData mentioned, citing a patient-based forecast.
Other main drugmakers growing weight-loss medication embody Pfizer (PFE) and Amgen (AMGN). Last week, AstraZeneca (AZN) inked a a deal value as much as $2B with China-based biotech Eccogene to develop an oral, once-daily GLP-1 receptor agonist for situations together with weight reduction.
“Nonetheless, it is anticipated that the competition between Eli Lilly and Novo Nordisk to win patient shares for this indication will be fierce and one to watch out for,” GlobalData’s Reci added.